• 1
    Apostolidis A, Dasgupta P, Denys P et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55: 10019
  • 2
    Mangera A, Andersson KE, Apostolidis A et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011; 60: 78495
  • 3
    Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49: 52835
  • 4
    Pinto R, Lopes T, Frias B et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 3605
  • 5
    Gamé X, Castel-Lacanal E, Bentaleb Y et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008; 53: 6138
  • 6
    Wefer B, Ehlken B, Bremer J et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol 2010; 28: 38590
  • 7
    Mouttalib S, Khan S, Castel-Lacanal E et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int 2010; 106: 167780
  • 8
    Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009; 103: 150915
  • 9
    Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009; 181: 260815
  • 10
    Mehnert U, Boy S, Schmid M et al. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 2009; 27: 397403
  • 11
    Schulte-Baukloh H, Knispel HH. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 95: 454
  • 12
    Thirunavukkarasusx N, Ghosal KJ, Kukreja R et al. Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin. Biochemical and Biophysical Research Communications 2011; 405: 68490
  • 13
    Kutzenberger J. Surgical therapy of neurogenic detrusor overactivity (hyperreflexia) in paraplegic patients by sacral deafferentation and implant driven micturition by sacral anterior root stimulation: methods, indications, results, complications, and future prospects. Acta Neurochir Suppl 2007; 97: 3339
  • 14
    Lopez Pereira P, Moreno Valle JA, Espinosa L et al. Enterocystoplasty in children with neuropathic bladders: long-term follow-up. J Pediatr Urol 2008; 4: 2731
  • 15
    Sievert KD, Amend B, Gakis G et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010; 67: 7484
  • 16
    Stohrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine compared to oxybutynin in neurogenic detrusor overactivity–results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007; 51: 23542
  • 17
    Vickrey BG, Shekelle P, Morton S, Clark K, Pathak M, Kamberg C. Prevention and management of urinary tract infections in paralyzed persons. Evid Rep Technol Assess (Summ) 1999; 6: 13
  • 18
    Schlager TA, Legallo R, Innes D, Hendley JO, Peters CA. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol 2011; 186: 235964
  • 19
    Schlager TA, Hendley JO, Peters CA. Absence of bacterial reservoirs in the bladder epithelium of patients with chronic bacteriuria due to neurogenic bladder. J Urol 2009; 182: 17149
  • 20
    Bjorling DE, Wang ZY, Bushman W. Models of inflammation of the lower urinary tract. Neurourol Urodyn 2011; 30: 67382
  • 21
    Kowalski ML, Sliwinska-Kowalska M, Kaliner MA. Neurogenic inflammation, vascular permeability, and mast cells. II. Additional evidence indicating that mast cells are not involved in neurogenic inflammation. J Immunol 1990; 145: 121421
  • 22
    Sharkey KA. Substance P and calcitonin gene-related peptide (CGRP) in gastrointestinal inflammation. Ann N Y Acad Sci 1992; 664: 42542
  • 23
    Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 12533
  • 24
    De Ridder DJ, Everaert K, Fernandez LG et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol 2005; 48: 9915